Lamotrigine added to antipsychotics for persistent schizophrenia symptoms
About this title
Read the official source — NCT00086593This study evaluated the safety and effectiveness of lamotrigine for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of lamotrigine for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 38 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 209
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00086593
- Official title
Show the full official title
A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock, United States · Garden Grove, United States · Glendale, United States
34 more locations
- Los Angeles, United States
- Pico Rivera, United States
- San Diego, United States
- Sherman Oaks, United States
- Coral Springs, United States
- Maitland, United States
- Miami, United States
- North Miami, United States
- Winter Park, United States
- Niles, United States
- Oak Brook, United States
- Indianapolis, United States
- Staten Island, United States
- Nashville, United States
- Bellaire, United States
- San Antonio, United States
- Madison, United States
- Edmonton, Canada
- Kelowna, Canada
- Winnipeg, Canada
- Miramichi, Canada
- Dartmouth, Canada
- Sydney, Canada
- Burlington, Canada
- Greater Sudbury, Canada
- London, Canada
- Mississauga, Canada
- Toronto, Canada
- Windsor, Canada
- Bedford, United Kingdom
- Cambridge, United Kingdom
- Glasgow, United Kingdom
- Coventry, United Kingdom
- Hull, United Kingdom
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of lamotrigine for people with schizophrenia.
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including lamotrigine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
